4XJ0

Crystal structure of ERK2 in complex with an inhibitor 14K


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.58 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.208 
  • R-Value Observed: 0.210 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.

Ren, L.Grina, J.Moreno, D.Blake, J.F.Gaudino, J.J.Garrey, R.Metcalf, A.T.Burkard, M.Martinson, M.Rasor, K.Chen, H.Dean, B.Gould, S.E.Pacheco, P.Shahidi-Latham, S.Yin, J.West, K.Wang, W.Moffat, J.G.Schwarz, J.B.

(2015) J Med Chem 58: 1976-1991

  • DOI: 10.1021/jm501921k
  • Primary Citation of Related Structures:  
    4XJ0

  • PubMed Abstract: 
  • Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation ...

    Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation.


    Organizational Affiliation

    Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Mitogen-activated protein kinase 1A, B349Homo sapiensMutation(s): 0 
Gene Names: MAPK1ERK2PRKM1PRKM2
EC: 2.7.11.24
UniProt & NIH Common Fund Data Resources
Find proteins for P28482 (Homo sapiens)
Explore P28482 
Go to UniProtKB:  P28482
PHAROS:  P28482
GTEx:  ENSG00000100030 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP28482
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
41B
Query on 41B

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl]pyridin-2(1H)-one
C22 H22 Cl F N4 O3
PGGLRAWFUJMQBN-HXUWFJFHSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
NEP
Query on NEP
A, B L-PEPTIDE LINKINGC6 H10 N3 O5 PHIS
Binding Affinity Annotations 
IDSourceBinding Affinity
41B BindingDB:  4XJ0 Ki: min: 0.4, max: 0.6 (nM) from 2 assay(s)
IC50: min: 1.1, max: 3.9 (nM) from 3 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.58 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.208 
  • R-Value Observed: 0.210 
  • Space Group: P 41 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 83.191α = 90
b = 83.191β = 90
c = 274.493γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
HKL-2000data reduction
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 



Entry History 

Deposition Data

  • Deposited Date: 2015-01-08 
  • Released Date: 2015-09-16 
  • Deposition Author(s): Yin, J., Wang, W.

Revision History  (Full details and data files)

  • Version 1.0: 2015-09-16
    Type: Initial release